<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005">
<channel xmlns:cfi="http://www.microsoft.com/schemas/rss/core/2005/internal" cfi:lastdownloaderror="None">
<title cf:type="text"><![CDATA[Editorial Board of Journal of Pharmaceutical Research -->Industrial Pharmacy]]></title>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[湿热灭菌设备的确认]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309024&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:32</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[苏雨]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>苏雨</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201309024&flag=1]]></guid><cfi:id>75</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[4’’-正戊氧基-1,1’∶4’,1’’-三联苯-4-甲酸的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:59</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[苗宇,关永霞]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>苗宇,关永霞</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201308025&flag=1]]></guid><cfi:id>74</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[山东省新修订药品GMP认证检查情况分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:37</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[韩莹,柏建学]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩莹,柏建学</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307018&flag=1]]></guid><cfi:id>73</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[厄他培南钠的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:03:37</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[郭树栋,白文钦,孙秀玲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>郭树栋,白文钦,孙秀玲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201307019&flag=1]]></guid><cfi:id>72</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[制药企业用化学消毒剂的选择及使用方法研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305026&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:24:14</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[李向梅,张雪梅,吴文琦]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李向梅,张雪梅,吴文琦</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201305026&flag=1]]></guid><cfi:id>71</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Control of key links and analysis of common problems in the freeze-drying process of drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303027&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 0:00:00</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[蔡继兰,叶东,汪宗华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>蔡继兰,叶东,汪宗华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201303027&flag=1]]></guid><cfi:id>70</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[金银花中绿原酸的工业化提取纯化方法探讨]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[凌益平<sup>1</sup>,吕芳<sup>2</sup>,骆雅琴<sup>1</sup>,朱晨<sup>1</sup>,郑严<sup>1</sup>,狄雅梅<sup>1</sup>,史立人<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>凌益平<sup>1</sup>,吕芳<sup>2</sup>,骆雅琴<sup>1</sup>,朱晨<sup>1</sup>,郑严<sup>1</sup>,狄雅梅<sup>1</sup>,史立人<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301020&flag=1]]></guid><cfi:id>69</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[如何降低乙酰谷酰胺氯化钠注射液的有关物质]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:29:43</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[李继强,李洁,崔健]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李继强,李洁,崔健</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201301021&flag=1]]></guid><cfi:id>68</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[实施2010版GMP对企业质量管理理念的影响]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312024&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:21</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[钱亚楠]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>钱亚楠</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312024&flag=1]]></guid><cfi:id>67</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[二氟泼尼酯的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:21</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[孔祥雨,刘宪华,赵思太,任业明,姜明俊]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孔祥雨,刘宪华,赵思太,任业明,姜明俊</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312025&flag=1]]></guid><cfi:id>66</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[吡喹酮中间体N-苯乙基氯乙酰胺的合成工艺改进]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312026&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:21</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[王风军<sup>1,2</sup>,马淑涛<sup>1</sup>,翟吉胜<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王风军<sup>1,2</sup>,马淑涛<sup>1</sup>,翟吉胜<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312026&flag=1]]></guid><cfi:id>65</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[酚磺乙胺的合成工艺改进]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312027&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:00:21</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[赵海桥<sup>1,2</sup>,范兴山<sup>1</sup>,王飞龙<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>赵海桥<sup>1,2</sup>,范兴山<sup>1</sup>,王飞龙<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201312027&flag=1]]></guid><cfi:id>64</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[注射剂可见异物研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311026&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:00</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[窦学杰,张丽宝,杨爱荣]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>窦学杰,张丽宝,杨爱荣</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311026&flag=1]]></guid><cfi:id>63</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[对2010版GMP质量控制实验室检查方法的探讨]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311027&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:01</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[刘晓哲]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘晓哲</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311027&flag=1]]></guid><cfi:id>62</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[罗氟司特中间体3-环丙基甲氧基-4-二氟甲氧基苯甲醛的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311028&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:01:01</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[周海洋,董旭,翟海民,陈明强]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>周海洋,董旭,翟海民,陈明强</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201311028&flag=1]]></guid><cfi:id>61</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[制剂企业药用辅料内控质量标准的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310023&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/24 15:02:00</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[安勇]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>安勇</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201310023&flag=1]]></guid><cfi:id>60</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[阿哌沙班的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:51</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[张涛<sup>1,2</sup>,孔令金<sup>1</sup>,丁珊珊<sup>1</sup>,刘新泳<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张涛<sup>1,2</sup>,孔令金<sup>1</sup>,丁珊珊<sup>1</sup>,刘新泳<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409018&flag=1]]></guid><cfi:id>59</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[4-氯-3-甲氧基-2-甲基吡啶的制备工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 15:15:51</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[孙新堂<sup>1</sup>,魏培<sup>1</sup>,桑林涛<sup>2</sup>,马寿欣<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>孙新堂<sup>1</sup>,魏培<sup>1</sup>,桑林涛<sup>2</sup>,马寿欣<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201409019&flag=1]]></guid><cfi:id>58</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[亚胺培南的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:30</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[武洪英,孙秀玲,白文钦]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>武洪英,孙秀玲,白文钦</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408019&flag=1]]></guid><cfi:id>57</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[雄烯二酮合成17α-羟基黄体酮的工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:10:30</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[李兴泰,李程鹏,刘云]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李兴泰,李程鹏,刘云</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201408020&flag=1]]></guid><cfi:id>56</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[基因工程菌发酵表达rhG-CSF的条件优化]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:23:47</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[王娟,李希平]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王娟,李希平</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201407018&flag=1]]></guid><cfi:id>55</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[影响替硝唑氯化钠注射液有关物质升高的因素及控制措施]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:18:18</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[王丽华,张雪梅,周峰]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王丽华,张雪梅,周峰</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201406020&flag=1]]></guid><cfi:id>54</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[制药用聚丙烯瓶坯拉丝及拖尾现象原因分析及解决办法]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405025&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:12:11</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[徐建民,边忠锋,张国锋,金曼,孙庆]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>徐建民,边忠锋,张国锋,金曼,孙庆</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201405025&flag=1]]></guid><cfi:id>53</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[沃替西汀的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:20</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[任世言<sup>1,2</sup>,孙钊<sup>2</sup>,张春华<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>任世言<sup>1,2</sup>,孙钊<sup>2</sup>,张春华<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404020&flag=1]]></guid><cfi:id>52</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[4-(4,6-二吗啉-1,3,5-三嗪-2-基)苯胺的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:06:20</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[矫春丽,陈彤]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>矫春丽,陈彤</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201404021&flag=1]]></guid><cfi:id>51</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[布地奈德的合成工艺改进]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 10:01:00</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[王宝伟,张贵民,王洪刚]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>王宝伟,张贵民,王洪刚</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201403021&flag=1]]></guid><cfi:id>50</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[2013年山东省新修订药品GMP认证检查情况分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402024&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/2/23 9:54:56</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[韩莹]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>韩莹</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201402024&flag=1]]></guid><cfi:id>49</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[奥扎格雷合成路线图解]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:23</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[张立娟<sup>1</sup>,宋铁兵<sup>2</sup>,杨姣<sup>2</sup>,张晓友<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>张立娟<sup>1</sup>,宋铁兵<sup>2</sup>,杨姣<sup>2</sup>,张晓友<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412020&flag=1]]></guid><cfi:id>48</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[芬戈莫德的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:23</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[刘剑峰<sup>1</sup>,苏鹏<sup>1</sup>,韩建奎<sup>1</sup>,侯桂华<sup>2</sup>,徐文方<sup>3</sup>,李月凯<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘剑峰<sup>1</sup>,苏鹏<sup>1</sup>,韩建奎<sup>1</sup>,侯桂华<sup>2</sup>,徐文方<sup>3</sup>,李月凯<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412021&flag=1]]></guid><cfi:id>47</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[塑料安瓿用于小容量注射剂包装的现状及发展趋势]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412022&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 11:06:23</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[刘绪贵,牛海岗,常征]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘绪贵,牛海岗,常征</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201412022&flag=1]]></guid><cfi:id>46</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[丙氨酸喹羟酮盐酸盐的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/22 13:16:34</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[吕淑荣<sup>1</sup>,刘哲林<sup>1</sup>,王晓洁<sup>1</sup>,侯建成<sup>2</sup>,梁爱军<sup>3</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>吕淑荣<sup>1</sup>,刘哲林<sup>1</sup>,王晓洁<sup>1</sup>,侯建成<sup>2</sup>,梁爱军<sup>3</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201411020&flag=1]]></guid><cfi:id>45</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[S-泮托拉唑钠的合成工艺改进]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2017/1/11 14:59:12</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[卢进城]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>卢进城</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201410020&flag=1]]></guid><cfi:id>44</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[伊曲茶碱合成工艺改进]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 9:10:27</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[李兴泰,李鹏程]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李兴泰,李鹏程</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201509021&flag=1]]></guid><cfi:id>43</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[洁净瓶胚料在塑瓶大输液生产中回收利用的研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508021&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/10 13:23:03</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[崔良峰,黄桂华]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>崔良峰,黄桂华</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201508021&flag=1]]></guid><cfi:id>42</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[依普利酮的合成]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[商艳梅,郑忠辉,赵淑娟]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>商艳梅,郑忠辉,赵淑娟</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506018&flag=1]]></guid><cfi:id>41</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[直立式聚丙烯输液袋装输液灭菌工艺研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[马晓红,陈学武,王忠宝,侯仁秀]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>马晓红,陈学武,王忠宝,侯仁秀</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506019&flag=1]]></guid><cfi:id>40</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[物料平衡若干问题探讨及对监管工作的启示]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/5/16 14:26:03</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[林超<sup>1</sup>,翟婷<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>林超<sup>1</sup>,翟婷<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201506020&flag=1]]></guid><cfi:id>39</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[右旋糖酐40氯化钠注射液沉淀物形成的影响因素及控制措施]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:07:52</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[许文东<sup>1，2</sup>,张雪梅<sup>2</sup>,秦文明<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>许文东<sup>1，2</sup>,张雪梅<sup>2</sup>,秦文明<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201505020&flag=1]]></guid><cfi:id>38</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[影响非PVC软包装输液漏液的因素及控制措施]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:33:18</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[刘素静,张雪梅,秦文明]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>刘素静,张雪梅,秦文明</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201503017&flag=1]]></guid><cfi:id>37</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[影响碳酸氢钠注射液质量的因素与控制措施]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:43:07</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[冯燕]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>冯燕</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201502018&flag=1]]></guid><cfi:id>36</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[苯甲酸阿格列汀合成工艺的改进]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[史丙月,郭新亮,王方]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>史丙月,郭新亮,王方</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501019&flag=1]]></guid><cfi:id>35</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[4-丙硫基邻苯二胺的制备工艺]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501020&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2016/9/19 14:58:20</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[冯思佳<sup>1</sup>,宋智梅<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>冯思佳<sup>1</sup>,宋智梅<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201501020&flag=1]]></guid><cfi:id>34</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Improved synthesis of 5-allyloxy-2,3,4-tris(benzyloxy)pentan-1-ol]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective<b>  To synthesize 5-allyloxy-2,3,4-tris(benzyloxy) pentan-1-ol.<b>Methods</b>  With D-ribose as the starting material,5-allyloxy-2,3,4-tris(benzyloxy) pentan-1-ol was obtained by glycosidation,benzylation,hydrolyzation,oxime protection,allylation, deoximation and reduction.<b>Results and Conclusion</b>  The overall yield of this method was 55%, and the structure of product was characterized by <sup>1</sup>H-NMR.The synthetic route was short and environmentally friendly, suitable for the industrial production．]]></description>
<pubDate>2016/3/29 9:07:19</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[XI Zun-bo<sup>1,2</sup>, LI Xin<sup>1</sup> and MA Shu-tao<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XI Zun-bo<sup>1,2</sup>, LI Xin<sup>1</sup> and MA Shu-tao<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201512017&flag=1]]></guid><cfi:id>33</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Synthesis of related substances of piracetam]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the chemical synthesis of one related substance of piracetam.<b>Methods</b>  One intermediate was synthesized from 4-amino butyric acid by esterification reaction,sulfonated reaction and other 4 steps reaction.4-(N-formamyl methyl) amino butyric acid was obtained by hydrolysis process of the intermediate in piperidine.<b>Results</b>  The structure of end product was confirmed by MS,<sup>1</sup>H-NMR.<b>Conclusion</b>  One related substance of piracetam was synthesized successfully in this study.This substance was taken as the reference for the quality control of piracetam.]]></description>
<pubDate>2016/8/8 10:12:09</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[XU Yuwen, ZHENG Jing and WANG Xiaobing]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Yuwen, ZHENG Jing and WANG Xiaobing</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201608016&flag=1]]></guid><cfi:id>32</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[New method for the synthesis of cinacalcet hydrochloride]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> A new method was developed for the synthesis of cinacalcet hydrochloride.<b>Methods</b>  Cinacalcet hydrochloride was prepared from 3-(3-trifluoromethylphenyl)-1-propanol via three steps,including DMSO/P<sub>2</sub>O<sub>5</sub> mediated oxidation,iron triflate catalyzed reductive amination of aldehydes using sodium borohydride,and finally hydrochloride formation.<b>Results and Conclusion</b>  This method used environmentally benign reagents to prepare cinacalcet hydrochloride in only three steps with an overall good yield of 57.8%.]]></description>
<pubDate>2016/7/12 14:11:37</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[LIU Wei and LIU Zhaopeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>LIU Wei and LIU Zhaopeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201607017&flag=1]]></guid><cfi:id>31</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Synthesis of rivaroxaban]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To study the chemical synthesis of rivaroxaban.<b>Methods</b> 4-(4-aminophenyl)morpholin-3-one was synthesized from p-Nitroaniline by ring-open and reduction,and then synthesized to rivaroxaban by addition,cyclization, deprotection and condensation.<b>Results</b>  The total yield was 32.1% (based on p-Nitroaniline) and the structure was confirmed by IR,<sup>1</sup>H-NMR and MS.<b>Conclusion</b>  This synthesis line showed more favorable and commercial value in the manufacture scale.]]></description>
<pubDate>2016/5/25 10:40:36</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[SUN Man<sup>1</sup>, LIU Weisup>2</sup> and SUN Qingweisup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SUN Man<sup>1</sup>, LIU Weisup>2</sup> and SUN Qingweisup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201605017&flag=1]]></guid><cfi:id>30</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Decolorizaing of pharmaceutical industry wastewater by complex method]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>    To study the decolorization technology of the pharmaceutical industry wastewater.<b>Methods</b>   Using COD,SS,BOD<sub>5</sub>,total nitrogen content and so on as the indexes, the pharmaceutical wastewater was treated by using the complex method (coagulation-oxygen-aerobic process),and the effect of the treatment was evaluated.<b>Results</b>   Pharmaceutical industry wastewater treatment by the complex method,the water quality was clear,and the nitrogen content was greatly reduced,the BOD<sub>5</sub> and COD were significantly decreased,and conforms to the discharge standard.<b>Conclusion</b>   The method is practical,the cost is low,and the operation is simple,so it can be applied in practical production.]]></description>
<pubDate>2016/5/5 15:59:03</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[HAN Fei<sup>1</sup>, KANG Guoxian<sup>1</sup>, WU Huaqiang<sup>1</sup>, LIU Youer<sup>1</sup>, LI Zhifeng<sup>2</sup>, XIE Weihua<sup>1</sup> and XIAO Xiong<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAN Fei<sup>1</sup>, KANG Guoxian<sup>1</sup>, WU Huaqiang<sup>1</sup>, LIU Youer<sup>1</sup>, LI Zhifeng<sup>2</sup>, XIE Weihua<sup>1</sup> and XIAO Xiong<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201604017&flag=1]]></guid><cfi:id>29</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the yellow bags after sterilization of non-PVC packaging large volume injections]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603018&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[By studying of non-PVC multi-layer co-extruded film properties,the sterilization process of non-PVC packaging of large volume injections and the characteristics of the water bath sterilizer,the authors found the reasons for making the bags yellow.And the issue on the yellow bags after sterilization of non-PVC packaging large volume injections can be solved by the methods of transformation and regular cleaning.]]></description>
<pubDate>2016/4/7 9:39:54</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[ZHOU Meili<sup>1,2</sup>, SONG Yanping<sup>2</sup> and ZAMG Hengchang<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHOU Meili<sup>1,2</sup>, SONG Yanping<sup>2</sup> and ZAMG Hengchang<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201603018&flag=1]]></guid><cfi:id>28</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Improved technology for synthesis of metoprolol succinate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602019&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To improve the synthesis process of metoprolol succinate.<b>Methods</b>  p-(2-Methoxyethyl) phenol and epichlorohydrin were taken as starting reagents. Tetrabutylammonium bromide was used to catalyze their reaction to get  1-(2,3-epoxypropoxy)-4-(2-methoxyethyl) benzene.And then AlCl<sub>3</sub> was used to catalyze the reaction of 1-(2,3-epoxypropoxy)-4-(2-methoxyethyl) benzene and  isopropyl amine to obtain metoprolol.Finally,metoprolol was treated with succinic acid to get metoprolol succinate.<b>Results</b>  The structure of metoprolol succinate was corroborated by <sup>1</sup>H-NMR and ESI-MS.The purity was 99.01%,while the total yield was 51.8%.<b>Conclusion</b>  This method was simple,moderate and environmentally- friendly.The product purity and yield were all high.It was suitable for industrialization of green production.]]></description>
<pubDate>2016/3/21 14:56:14</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[HOU Yaqin, LIU Caijuan, ZUO Junming, CUI Guangzhi and MOU Jiajia]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HOU Yaqin, LIU Caijuan, ZUO Junming, CUI Guangzhi and MOU Jiajia</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201602019&flag=1]]></guid><cfi:id>27</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Research on water distribution uniformity confirmation method of water bath sterilizer]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To establish a water bath sterilizer confirmed the uniformity of water distribution method,and evaluate the uniformity of water distribution sterilizer.<b>Methods</b>  Through the analysis of water bath sterilizer water distribution structure, the spiral wing type water meter installed in the nozzle of cloth on cloth outlet water in different time measurement,the obtained data was analyzed by significant difference test and <i>RSD</i> analysis,and to confirm that the water distribution was whether or not uniform.<b>Results</b>  Through statistical analysis of the flow data of unit time,the significant difference test (test significance) results for  <i>P</i> value of 15 min traffic data was 0.004(indicating that the difference is very significant),  <i>P</i> value of 30 min flow data was 0.963 (indicating that the difference is not significant), P value of60min traffic data was 0.024(indicated significant difference); <i>RSD</i> results from 2.3% to 2.9%.<b>Conclusion</b>   <i>RSD</i> of water monitoring data obtained from cloth outlet of spiral wing type water meter were statistically evaluated to confirm the water bath sterilizer water distribution uniformity for providing a simple and accurate method.]]></description>
<pubDate>2016/3/22 10:16:56</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[XU Wendong<sup>1,2</sup>, YU Peng<sup>2</sup>, WANG Changcheng<sup>2</sup>, MA Xiujuan<sup>2</sup> and YUAN Jiangtao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Wendong<sup>1,2</sup>, YU Peng<sup>2</sup>, WANG Changcheng<sup>2</sup>, MA Xiujuan<sup>2</sup> and YUAN Jiangtao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201601017&flag=1]]></guid><cfi:id>26</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discussion on the control of Hydroxyethyl starch series raw material quality]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This paper briefly described the classification of a series of hydroxyethyl starch APIs,clinical adverse reactions associated with key indicators of quality control and research situations according to the literature and reports.Moreover,it emphasized the importance of unified quality standards of a series of hydroxyethyl starch APIs.]]></description>
<pubDate>2016/12/29 13:59:16</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[QI Lin<sup>1,2</sup>, CHEN Renping<sup>1</sup>, LIAN Chuanbao<sup>3</sup> and YIN Jianfeng<sup>4</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QI Lin<sup>1,2</sup>, CHEN Renping<sup>1</sup>, LIAN Chuanbao<sup>3</sup> and YIN Jianfeng<sup>4</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201612015&flag=1]]></guid><cfi:id>25</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on the synthesis of lormetazepam]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To study the synthesis process of lormetazepam.<b>Methods</b>  To synthesis lormetazepam with 2-amino-2',5-dichloro benzophenone as raw materials.The whole process including oxime reaction,expansion reaction,methylation reaction,acetylation reaction and alkaline hydrolysis reaction.Finally,the product of lormetazepam was obtained by twice ethanol refining.<b>Results and Conclusion</b>  The structure of target compound was definited by<sup>1</sup>H-NMR,<sup>13</sup>C-NMR,MS.The total yield reached 20%.The operation of synthesis process of reactants was simple,the intermediate quality yield was stable,was suitable for industrial production.]]></description>
<pubDate>2017/8/30 13:48:11</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[WANG Wei<sup>1</sup>, LI Xingtai<sup>2</sup>, ZHANG Fuqiang<sup>2</sup> and CHANG Sen<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Wei<sup>1</sup>, LI Xingtai<sup>2</sup>, ZHANG Fuqiang<sup>2</sup> and CHANG Sen<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201708015&flag=1]]></guid><cfi:id>24</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis the policies about the procedures and contents on generic drug quality equivalence assessment]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[In order to develop the generic drug quality equivalence assessment, China Food and Drug Administration (CFDA) introduce a lot of policies and technical guidelines.Based on the induction summary,this review discussed the procedures and contents of generic drug quality equivalence assessment to provide reference for evaluation of the consistency.]]></description>
<pubDate>2017/5/23 16:01:10</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[ZHANG Liying<sup>1</sup>, LIU Xuliang<sup>2</sup> and ZHANG Libao<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHANG Liying<sup>1</sup>, LIU Xuliang<sup>2</sup> and ZHANG Libao<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201705016&flag=1]]></guid><cfi:id>23</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Factor analysis on fragmentation of polypropylene combination closures of plastic infusion containers]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b> To analysis the influencing factors of fragmentation when the polypropylene combination closures being penetrated,reduce the amount of the fragmentation by improving combination closures.<b>Methods</b> The best combination closures were decided by researching the effect of the structure and material of combination closures to the fragmentation of combination closures.<b>Results</b>  Increase the amount of the elastomers in inner cover,increase the rubber content  of  gasket  and reduce the thickness of the puncture may evidently improve the resist fragmentation properties of the combination closures.<b>Conclusion</b>  This paper improved the resist fragmentation properties of the combination closures by analyzing factors influencing on fragmentation of combination closures.]]></description>
<pubDate>2017/5/2 14:32:10</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[AN Yonghua<sup>1</sup>, REN Dayong<sup>1</sup>, QI Lin<sup>1</sup>, ZHAO Junlian<sup>2</sup> and LIU Zhenzhen<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>AN Yonghua<sup>1</sup>, REN Dayong<sup>1</sup>, QI Lin<sup>1</sup>, ZHAO Junlian<sup>2</sup> and LIU Zhenzhen<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201704016&flag=1]]></guid><cfi:id>22</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The influencing factors and controlling measures of upright PP-bag]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the influencing factors that affect the quality of upright PP-bag products,and raise the controlling measures.<b>Methods</b>  To analyze the influencing factors,technical parameters in producing and the influencing factors in transportation,storage and using process of upright PP-bag products. <b>Results</b>  Each parameter in the production process affected the appearance and bag type directly,and storage conditions and clinical application affected the quality of using.<b>Conclusion</b>  There were many and complicated  influencing factors for the product quality of upright PP-bag,it needed to strictly control each influencing factors for ensuring and raising the product quality.]]></description>
<pubDate>2017/4/17 14:20:01</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[QI Gaoqing<sup>1</sup>, YIN Jianfeng<sup>2</sup>, ZHU Yuyan<sup>1</sup> and WANG Bin<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>QI Gaoqing<sup>1</sup>, YIN Jianfeng<sup>2</sup>, ZHU Yuyan<sup>1</sup> and WANG Bin<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201703017&flag=1]]></guid><cfi:id>21</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on the data integrity of chromatographic system of sterile pharmaceutical production enterprises in Shandong Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The annex "Computerized System" to "Good Manufacturing Practice (2010 Revision)" came into effect since December 1,2015,which proposed clear request on data integrity of the computerized system.Many domestic enterprises were found to be still weak in data integrity based on the inspection since 2015.Through the investigation on the data integrity of chromatographic system of sterile drug production enterprises in Shandong Province,this paper aimed to find out the weaknesses of data integrity,evaluate the risks of data integrity and prompt enterprises to upgrade to meet the requirements of the annex.]]></description>
<pubDate>2017/3/28 14:39:39</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[HAN Ying and HU Jingfeng]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HAN Ying and HU Jingfeng</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201702017&flag=1]]></guid><cfi:id>20</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[The improvement of synthesis process for sildenafil citrate and its key intermediate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To optimize and improve the synthesis process for sildenafil citrate and its key intermediate sildenafil.<b>Methods</b>  The sildenafil citrate was prepared from the raw materials of 2-ethoxybenzoyl chloride and 4-amino-1-methyl-3-n-propyl-5-pyrazolecarboxamide by the reactions of condensation,cyclization,chlorosulfonation,sulfonamide and salt.<b>Results</b>  The purity of the key intermediate sildenafil was higher than 99.5%,impurity D(EP) was lower than 0.3% and the unspecified single impurity was lower than 0.15%.<b>Conclusion</b>  The purity of the sildenafil citrate was above 99.8% and the total yield was 45%.The process was low cost,easy operate and suitable for industrialized production.]]></description>
<pubDate>2017/10/24 9:20:11</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[XU Lili<sup>1,2,3</sup>, WANG Haiyang<sup>1,2</sup>, KONG Yi<sup>4</sup> and YAO Qingqiang<sup>1,2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XU Lili<sup>1,2,3</sup>, WANG Haiyang<sup>1,2</sup>, KONG Yi<sup>4</sup> and YAO Qingqiang<sup>1,2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201710016&flag=1]]></guid><cfi:id>19</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on defective items of drug GMP certification inspection for Shandong Province in 2017]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To discover the common deficiency in production quality management existing in pharmaceutical enterprises，and analyze the existing main risk point and provide reference for implementing standard GMP.<b>Methods</b>  Statistical analysis approached on the evaluation inspection results of pharmaceutical enterprises in Shandong Province in 2017.<b>Results and Conclusion</b>  The company should focus on the quality risk and make improvement in institutions and personnel，validation and verification，quality control and quality assurance，data integrity.]]></description>
<pubDate>2018/8/27 10:55:11</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[CAO Hongyan and HAN Ying]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>CAO Hongyan and HAN Ying</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201808015&flag=1]]></guid><cfi:id>18</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Bacteria detection for inside of the combination closures before and after disinfection of plastic infusion containers]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To investigate the sterility of the inside of the combination closures of Polypropylene plastic infusion containers with pull-open or pull-off cap.<b>Methods</b>  A total of 200 plastic infusion containers with pull-open or pull-off cap were randomly selected and divided into experimental group and control group,100 bottles in each group.All the plastic infusion containers were opened in the same experiment environment,the samples were collected directly with collecting bacteria instrument in the experimental group,and the samples were collected after disinfection in the control group.Samples in both groups were cultured with constant-temperature culture environment,and bacterial growth was observed in the two groups.<b>Results</b>  Samples with bacterial culture in both groups showed no bacterial growth.<b>Conclusion</b>  The inside of the combination closures of Polypropylene plastic infusion containers with pull-open or pull-off cap are sterile.]]></description>
<pubDate>2018/8/1 16:47:06</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[AN Yonghua, REN Dayong and XING Yanfang]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>AN Yonghua, REN Dayong and XING Yanfang</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201807017&flag=1]]></guid><cfi:id>17</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Discuss on the choose and common problems of steriliaztion process of injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Sterility is an important process for quality control and safety of injection,in this paper,the choose and common problems of steriliaztion process of injection,such as choose and validation of steriliaztion process,common problems in steriliaztion process of injection were discussed,based on the daily evalution experiences.]]></description>
<pubDate>2018/7/6 16:37:45</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[XIE Jizhen, FENG Qiaoqiao, LIU Juntian, ZHOU Chong and MA Lingling]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIE Jizhen, FENG Qiaoqiao, LIU Juntian, ZHOU Chong and MA Lingling</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201806017&flag=1]]></guid><cfi:id>16</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of isosorbide mononitrate and its patent protection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[This article was compiled for the cardiovascular and cerebrovascular disease states.Based on the pathogenesis of coronary heart disease and angina pectoris, according to the type and mechanism of prevention and treatment of coronary heart disease,the status of patent protection of isosorbide mononitrate was analyzed from the perspective of patent protection.It provided reference in the market evaluation, patent application and intellectual property protection for the drug manufacturing enterprises。]]></description>
<pubDate>2018/6/13 9:41:49</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[MA Qingwen, LIU Qingdong, ZHAO Wei and SHEN Qiangyu]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Qingwen, LIU Qingdong, ZHAO Wei and SHEN Qiangyu</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805014&flag=1]]></guid><cfi:id>15</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Synthesis of impurity D of clopidogrel hydrogen sulfate]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To synthesize impurity D of clopidogrel hydrogen sulphate.<b>Methods</b>  Methyl (2R)-(2-chlorophenyl)[(2S)-(2-chlorophenyl)-(2-amino)acetyloxy] acetate was obtained from (S)-(+)-methyl-α-amino(2-chlorophenyl)acetate through amino protection, esterification with (R)-2-chloro mandelic acid methyl ester and deprotection. Then it reacted with 2-(2-thienyl)ethyl toluene-p-sulphonate and clopidogrel hydrogen dulphate impurity D: methyl (2R)-(2-chlorophenyl)[(2S)-(2-chlorophenyl)[6,7dihydrothieno[3,2-c]pyridin-5(4H)-yl]-acetyloxy] acetate was synthesized after salification and cyclization.<b>Results</b>  The total yield of the designed route of impurity D was 54% and its HPLC purity was above 99.0%.<b>Conclusion</b>  Impurity D was of high purity and could be used as reference substance in the impurity research of clopidogrel hydrogen sulphate.]]></description>
<pubDate>2018/6/13 9:41:49</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[YANG Xueqian, HUANG Cuiping, WANG Shuilian, ZHAI Min and ZHANG Tao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Xueqian, HUANG Cuiping, WANG Shuilian, ZHAI Min and ZHANG Tao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201805015&flag=1]]></guid><cfi:id>14</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Study on optimization of central air conditioning system in soft capsule production workshop]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804017&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The process environment of soft capsules production is strictly required that needs to be maintained low temperature and low humidity for long periods. The rotary desiccant wheel central air-conditioning system (RDWCAC) is the usual method to dehumidification, which is disadvantage due to the high energy consumption and regular replacement of desiccant. To solve this problem, this paper designed a new type of energy efficient heat pipe heat pump central air-conditioning system (HPHPCACS).Through comparing the technical and economical indexes of HPHPCACS with RDWCAC and introducing the practical operational effect of HPHPCAC, the results showed that the new type of HPHPCAC can satisfy the requirement of the technological process of soft capsules production and had remarkable energy saving effect. It was worthy of overall promoting to conserve energy and reduce emissions.]]></description>
<pubDate>2018/5/23 17:07:56</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[WANG Longjiang<sup>1</sup>, DONG Hongjun<sup>1</sup>, YANG Jinlong<sup>1</sup>, LI Gang<sup>2</sup>, LI Xiaohua<sup>2</sup>, TIAN Xiaoliang<sup>2</sup> and QIN Xiaojie<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WANG Longjiang<sup>1</sup>, DONG Hongjun<sup>1</sup>, YANG Jinlong<sup>1</sup>, LI Gang<sup>2</sup>, LI Xiaohua<sup>2</sup>, TIAN Xiaoliang<sup>2</sup> and QIN Xiaojie<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201804017&flag=1]]></guid><cfi:id>13</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Synthesis of a new compounds of platinum]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  In this paper,a new synthesis methods of platinum anticancer drugs was introduced,as well as the drug in vitro inhibitory effect on liver cancer.<b>Methods</b>  The drugs used cholic acid as the carrier,and chelated to platinum,formed organic compounds of platinum.<b>Results</b>  In vitro experiments showed that bile acid platinum can inhibit the growth of liver cancer cell line BEL-7402 and HepG2.<b>Conclusion</b>  The anticancer effect of cholate platinum was significantly higher than that of cisplatin.]]></description>
<pubDate>2018/3/26 15:43:50</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[XIAO Yi]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>XIAO Yi</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201802016&flag=1]]></guid><cfi:id>12</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Development Trends Analysis of Medical Device Industry]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[The market demand for medical devices in China is growing rapidly.The products are still mainly at the middle and low end, and the innovation ability of enterprises is insufficient. However, compared with the international market, there is still a big gap.Facing the monopoly of foreign enterprises on medical devices,Chinese medical device industry seizes the opportunity of economic development and technological innovation, promotes the upgrading of medical device manufacturing industry and industrial innovation.The current situation and problems of the medical device industry in China as well as the development environment and policy support of enterprises were analyzed.Compared the gap between Chinese medical device industry and developed countries,analyses the boosting effect of industrial policies on the development of medical device industry.]]></description>
<pubDate>2019/1/14 14:42:23</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[YANG Yinyi<sup>1</sup>, CHEN Yidan<sup>2</sup> and LIU Yongjun<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>YANG Yinyi<sup>1</sup>, CHEN Yidan<sup>2</sup> and LIU Yongjun<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201812015&flag=1]]></guid><cfi:id>11</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the current situation of the development of traditional Chinese medicine industry in Jiangxi]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Basing on the theme of traditional Chinese medicine industry development,this paper analyzed the opportunities and advantages of the development of traditional Chinese medicine industry in Jiangxi Province.At the same time,it put forward to the current situation of the development and the problems in the developing procession of the traditional Chinese medicine industry in Jiangxi Province, and provided some suggestions to improve the traditional Chinese medicine industry standard in Jiangxi Province,and hoping to contribute to the development of Traditional Chinese Medicine industry in Jiangxi.]]></description>
<pubDate>2018/12/3 10:00:46</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[WEI Guobing<sup>1</sup>, LI Chenghu<sup>2</sup> and HU Qijun<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>WEI Guobing<sup>1</sup>, LI Chenghu<sup>2</sup> and HU Qijun<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201811015&flag=1]]></guid><cfi:id>10</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and control of visible particles in Fluconazole and Sodium Chloride Injection]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze the causes of visible particles in Fluconazole and Sodium Chloride Injection, formulate the controllable measures and improve, to insure the quality of production.<b>Methods</b> The fishbone diagram was used to analyze all aspects in the production process,summarize the causes of the visible particles and control.<b>Results</b>  Through the summary of each factor, keeping control strictly in Fluconazole and Sodium Chloride Injection’s production process, to form an effective visible particles control measures.<b>Conclusion</b>  Visible particles direct affects the quality and corporate imagement, so it is necessary to perform the controllable management, to realize the controllable management of visible particles.]]></description>
<pubDate>2019/6/27 10:49:44</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[KOU Min, SU Zhen<sup>1</sup>, ZHU Yuyan<sup>1</sup> and YU Hui<sup>2</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>KOU Min, SU Zhen<sup>1</sup>, ZHU Yuyan<sup>1</sup> and YU Hui<sup>2</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201906014&flag=1]]></guid><cfi:id>9</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of patent technology of antidiabetics——SGLT-2 inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[SGLT-2 inhibitors are novel medicines for treating type 2 diabetes.The research status of SGLT-2 inhibitors were reviewed in this paper.The number of SGLT-2 inhibitor related patent applications,as well as the applicants,and important applications were analyzed.The technology development process of SGLT-2 inhibitors were introduced.]]></description>
<pubDate>2019/6/3 16:05:49</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[HOU Qin, ZHOU Qiong, ZHAO Chunlin and ZHANG Jingsai]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>HOU Qin, ZHOU Qiong, ZHAO Chunlin and ZHANG Jingsai</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201905014&flag=1]]></guid><cfi:id>8</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on patented anti-respiratory syncytial virus drugs]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Respiratory syncytial virus (RSV) is the most common and most important pathogen causing acute lower respiratory tract infection in children under 2 years old. Based on the patent application literature of anti-respiratory syncytial virus. This paper sorts out the status quo of its technology development, domestic and foreign patent application situation, technology distribution, key applicants, etc. indicating that developed countries as Europe and America are absolutely leading in the research of anti-respiratory syncytial virus drugs. Status, China has been in a stage of rapid development in recent years.]]></description>
<pubDate>2019/4/12 10:55:30</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[MA Yongtao, SHEN Fang, ZHANG Xionghui and WANG Jingping]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>MA Yongtao, SHEN Fang, ZHANG Xionghui and WANG Jingping</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201903013&flag=1]]></guid><cfi:id>7</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis of the patents about PTP1B inhibitors]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Protein tyrosine phosphatase 1B (PTP1B) is a potential important target for the treatment of type 2 diabetes, and is closely related to obesity and tumors. By analyzing the patent distribution for PTP1B inhibitors, especially focusing on the patent situation and representative patents of the synthetic PTP1B inhibitors,we provided useful information on how to utilize and operate pharmaceutical patents for domestic drug development．]]></description>
<pubDate>2019/3/29 12:07:30</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[SHEN Fang, MA Yongtao, ZHANG Xionghui and LI Yao]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>SHEN Fang, MA Yongtao, ZHANG Xionghui and LI Yao</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201902014&flag=1]]></guid><cfi:id>6</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis on varieties and progress of consistency evaluation of generic drugs quality and efficacy in Hainan Province]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901015&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[Consistency evaluation of generic drugs quality and efficacy means evaluating the quality of generic drugs that have been approved for listing according to the same principle as the quality and curative effect of the original drug partially and in blocks. In order to promote consistency evaluation of generic drugs in Hainan province , the data related to the category, number and distribution of generic drugs manufactured in Hainan which are required to pass consistency evaluation by the end of 2018 were collected from the information management system of Drug approval number in Hainan (Qionglan file-management system).Meanwhile,the difficulties that enterprises faced and work process were investigated.This work has offered references for the enterprises and departments involved in consistency evaluation of generic drugs,and also provided data supports for the innovation of bio-pharmaceutical development policies in Hainan Province.]]></description>
<pubDate>2019/3/1 11:18:20</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[ZHU Ming, ZHANG Hui, CHANG Limei and LIN Kai]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHU Ming, ZHANG Hui, CHANG Limei and LIN Kai</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201901015&flag=1]]></guid><cfi:id>5</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[一次性使用精密过滤输液器（TPE输液器）的药物相容性研究]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912013&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2020/1/16 10:21:56</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[李蕾<sup>1</sup>,彭贤光<sup>1</sup>,刘一怡<sup>2</sup>,李风月<sup>1</sup>]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>李蕾<sup>1</sup>,彭贤光<sup>1</sup>,刘一怡<sup>2</sup>,李风月<sup>1</sup></atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201912013&flag=1]]></guid><cfi:id>4</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[CDK4/6抑制剂palbociclib专利技术分析]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910011&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[]]></description>
<pubDate>2019/10/15 9:11:55</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[蒋薇薇]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>蒋薇薇</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=201910011&flag=1]]></guid><cfi:id>3</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Synthesis of Related Substances of Levocarnitine]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005014&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To synthesize impurity A、impurity C and impurity D of Levocarnitine.<b>Methods</b>  (E)-4-(trimethylammonio)but-2-enoate (Impurities A) was obtained from Levocarnitine through dehydration. (2R)-4-amino-2-hydroxy- N,N,N-trimethyl-4-oxobutan-1-aminium chloride (Impurities C hydrochloride) was obtained from (R)-Epichlorohydrin through open-loop by aminolysis, cyanyl substitution and hydrolysis of hydrochloric acid. (E)-4-amino-N,N,N-trimethyl-4-oxobut-2-en-1-aminium (Impurities D) was obtained from impurity A through forming methyl Ester and ammoniolysis.<b>Results</b>  Three impurities were designed and synthesized. Their content were above 95.0%.<b>Conclusion</b>  Impurity A、impurity C and impurity D were of high purity and could be used as reference substance in the impurity research of Levocarnitine.]]></description>
<pubDate>2020/5/28 11:25:46</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[REN Jibo, YU Jianhua, LIU Ying, GAO Ying and YANG Xueqian]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>REN Jibo, YU Jianhua, LIU Ying, GAO Ying and YANG Xueqian</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202005014&flag=1]]></guid><cfi:id>2</cfi:id><cfi:read>true</cfi:read></item>
<item>
<title xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="text"><![CDATA[Analysis and control of airborne particles in the clean zone]]></title>
<link><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103016&flag=1]]></link>
<description xmlns:cf="http://www.microsoft.com/schemas/rss/core/2005" cf:type="html"><![CDATA[<b>Objective</b>  To analyze and find the influencing factors of the abnormal airborne particles in the clean zone，take control，to insure the production environment.<b>Methods</b>  Use the fishbone diagram to analyze all aspects, summarized the causes of the airborne particles and control.<b>Results</b>  Through the summary of each factor, keeping control strictly in all links,to achieve the desired affection.<b>Conclusion</b>  Airborne particles are affected by many factors,so it’s necessary to achieve corresponding protective measures,to ensure the stability of the clean zone .]]></description>
<pubDate>2021/4/19 9:34:30</pubDate>
<category><![CDATA[Industrial Pharmacy]]></category>
<author><![CDATA[ZHU Yuyan]]></author>
<atom:author xmlns:atom="http://www.w3.org/2005/Atom">
<atom:name>ZHU Yuyan</atom:name>
</atom:author>
<guid><![CDATA[http://www.yaoxueyanjiu.org.cn/ch/reader/view_abstract.aspx?file_no=202103016&flag=1]]></guid><cfi:id>1</cfi:id><cfi:read>true</cfi:read></item>
</channel>
</rss>